Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Parniak

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Antimicrobial Agents and Chemotherapy|May 23, 2002
A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitorsDimitrios Motakis, Michael A Parniak
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 16, 2001
HIV resistance to zidovudine: the role of pyrophosphorolysisDominique Arion, Michael A. Parniak
Journal of Virology|April 14, 2006
In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1Mohammad M Hossain, Michael A Parniak
Journal of Virology|September 6, 2005
Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domainMichael E Abram, Michael A Parniak
Molecular Pharmacology|July 20, 2002
Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitorsNicolas Sluis-Cremer, Dominique Arion, Michael A Parniak
Protein Science : a Publication of the Protein Society|August 22, 2003
Structure-activity relationships in HIV-1 reverse transcriptase revealed by radiation target analysisNicolas Sluis-Cremer, Ellis Kempner, Michael A Parniak
Retrovirology|February 4, 2010
The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage siteMichael E Abram, Stefan G Sarafianos, Michael A Parniak
Virology|September 13, 2011
The effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TCCaroline A Davis, Michael A Parniak, Stephen H Hughes
Plos One|May 1, 2008
Utilization of a deoxynucleoside diphosphate substrate by HIV reverse transcriptaseScott J Garforth, Michael A Parniak, Vinayaka R Prasad
AIDS Research and Human Retroviruses|August 9, 2002
Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitorGadi Borkow, Horacio Salomon, Mark A Wainberg, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|May 23, 2002
A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitorsDimitrios Motakis, Michael A Parniak
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 16, 2001
HIV resistance to zidovudine: the role of pyrophosphorolysisDominique Arion, Michael A. Parniak
Journal of Virology|April 14, 2006
In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1Mohammad M Hossain, Michael A Parniak
Journal of Virology|September 6, 2005
Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domainMichael E Abram, Michael A Parniak
Molecular Pharmacology|July 20, 2002
Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitorsNicolas Sluis-Cremer, Dominique Arion, Michael A Parniak
Protein Science : a Publication of the Protein Society|August 22, 2003
Structure-activity relationships in HIV-1 reverse transcriptase revealed by radiation target analysisNicolas Sluis-Cremer, Ellis Kempner, Michael A Parniak
Retrovirology|February 4, 2010
The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage siteMichael E Abram, Stefan G Sarafianos, Michael A Parniak
Virology|September 13, 2011
The effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TCCaroline A Davis, Michael A Parniak, Stephen H Hughes
Plos One|May 1, 2008
Utilization of a deoxynucleoside diphosphate substrate by HIV reverse transcriptaseScott J Garforth, Michael A Parniak, Vinayaka R Prasad
AIDS Research and Human Retroviruses|August 9, 2002
Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitorGadi Borkow, Horacio Salomon, Mark A Wainberg, et al.
Pageof 9